Navigation Links
Imagenetix Announces Issuance of New U.S. Patent for the Prevention and Treatment of Periodontal Disease
Date:11/4/2009

SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), announced today the issuance of a new U.S. patent (No. 7,612,111). The patent provides intellectual property protection for Imagenetix's 1-TDC early stage drug candidate for the prevention and treatment of periodontal disease.

Commenting on the patent issuance, Mr. William P. Spencer, President of Imagenetix, said, "The issuance is a significant development relating to our novel technology in the therapeutic treatment of periodontal disease and other inflammatory related conditions. Imagenetix now owns a broader range of intellectual property protection on our novel technology with the issuance of this U.S. patent. Through the guidance of Imagenetix's scientists and consultants, who are experts in achieving drug approval in this field, we continue to move forward with our promising drug therapy for the treatment of periodontitis."

Imagenetix's early stage drug candidate (1-TDC) has been studied at Boston University's Department of Periodontology and Oral Biology for the treatment of periodontal disease. In studies published in the Journal of Periodontology, 1-TDC was shown to stop the progression of periodontal disease in a rabbit periodontitis model. Studies at Boston University also demonstrated significant improvement and restoration in tissue and bone health compared to the placebo group.

About Imagenetix

Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates proprietary over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Please visit, www.celadrin.com, www.bioguardhealth.com or www.imagenetix.net.

Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected. Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company's SEC filings, including its Form 10-K for the year ended March 31, 2009.

             Contact   Imagenetix Investor Relations     William P. Spencer
                       (858)385-2797                Chief Executive Officer
                                                           Imagenetix, Inc.
                                                        Tel: (858) 674-8455

SOURCE Imagenetix, Inc.


'/>"/>
SOURCE Imagenetix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Letter to Shareholders From Imagenetix, Inc. President/CEO William Spencer
2. Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Using Neuronascents Neurogenesis Platform
3. BD Announces Results for Fourth Fiscal Quarter and Full Year
4. WebMD Health Corp. Announces Intention To Commence Tender Offer To Repurchase Up To 5,700,000 Shares of its Common Stock
5. Mettler-Toledo International Inc. Announces Webcast of Presentation at Baird Industrial Conference
6. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
7. West Announces Third Quarter 2009 Results
8. Rigel Announces Third Quarter 2009 Financial Results
9. VIVUS Announces Promotion of Peter Tam to President
10. ATS Medical Announces Third Quarter 2009 Results
11. BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):